Introduction
============

Indigenous intestinal bacteria are known to be equipped with an array of genes coding for uptake systems and complex enzymatic machinery that facilitates the utilization of oligo- and poly-saccharides. This constitutes a major adaptation mechanism to the main energy sources available in the large intestine for symbiotic bacteria ([@B29]). The role of breast-feeding in defining the composition of the gut microbiota, characterized by the dominance of bifidobacteria in infants, constitutes the best example of this adaptation process ([@B50]; [@B48]; [@B46]). Human milk oligosaccharides are highly diverse and complex glycans, which seem to have evolved naturally, shaping the species that inhabit the infant gut ([@B30]). Thus, species of the genus *Bifidobacterium* that predominate in breast-fed babies (*B. longum* subsp. *infantis* and *B. bifidum*, the so-called infant-type bifidobacteria) are known to possess the genetic and protein machinery (oligosaccharide binding proteins, fucosidases, lacto-*N* biosidase, etc.) necessary to utilize human-milk oligosaccharides. This confers a competitive advantage to bifidobacteria, whereby they outnumber other intestinal bacteria ([@B63]; [@B20]; [@B61]). This adaptation to diet may, in turn, also define the symbiotic host--microbe interactions and their biological role in human health ([@B55]). Epidemiological studies have demonstrated that breast-feeding confers benefits for early and long-term health, improving intestinal transit and reducing the incidence of infections and non-communicable diseases (e.g., obesity and type-2 diabetes; reviewed by [@B55]). It is not easy to confirm whether these effects are a direct consequence of the human-milk-induced microbiota pattern; however, it is biologically plausible that bifidobacteria play a potential role, which is supported to some extent by existing clinical ([@B9]; [@B39]; [@B55]) and pre-clinical data ([@B10]; [@B23]; [@B43], [@B42]; [@B53]; [@B17]; [@B58]). Consequently, alternative oligosaccharides have been produced to try to mimic the role of human milk oligosaccharides in the infant's microbiota, as well as to exert "bifidogenic" effects in adults, in the form of food ingredients or supplements ([@B37]). Among these, long-chain inulin-type fructans (FOS) and short-chain galacto-oligosaccharides (GOS) are the most commonly used, particularly in infant formula attempting to provide the beneficial effects of breast-milk ([@B47]). Nevertheless, further research is required to develop oligosaccharides that more closely resemble their natural counterparts, and to shed light on their interactions with specific indigenous bacteria, as well as their health consequences.

Studies *in vivo* reveal that lactulose-derived GOS (GOS-Lu) have higher resistance to gastrointestinal digestion and less absorption in the small intestine of rats than GOS derived from lactose. These properties were attributed to the strong resistance of galactosyl-fructoses to the hydrolytic action of mammalian digestive enzymes ([@B26]). Conventional GOS (derived from lactose) and GOS-Lu bear different structural features based not only on monosaccharide composition but also on the degree of polymerization, anomeric configuration, isomer composition and types of glycosidic linkage. Specifically, the predominant glycosidic linkage type in GOS-Lu is β-(1→6), whereas the main glycosidic linkage present in commercial GOS is β-(1→4) for instance Vivinal^®^(Friesland Campina, The Netherlands). Additionally, GOS-Lu also contains galactosyl-fructoses and galactobioses containing 1→2 and 1→5 linkages, which are not found in conventional GOS. These differences in glycosidic linkage types are thought to be crucial in the potential bioactivity of GOS-Lu type oligosaccharides.

In this study, we have investigated the ability of *Bifidobacterium pseudocatenulatum* CECT 7765, isolated from stools of a breast-fed infant, to utilize galacto-oligosaccharides. This is the first attempt to understand its origin, as this is generally considered to be an adult-type bifidobacterium, and to improve its functionality as a potential probiotic, bearing in mind this strain has proven pre-clinical efficacy in obesity and cirrhosis experimental models ([@B10]; [@B43], [@B42]). In addition, we have evaluated the potential advantage of using a GOS-Lu instead of a GOS because of its persistence in the intestine and slower fermentation in proximal colon ([@B11]; [@B38]; [@B26]), as well as its capacity to selectively stimulate the growth and/or activity of bifidobacterial species ([@B36]). Previous research also shows GOS-Lu are effective in a rat model of experimental colitis, presumably by exerting immunomodulatory effects associated with increased short-chain fatty-acid production ([@B2]). Additionally, the presence of non-transgalactosylated lactulose, a prebiotic, instead of lactose in the GOS-Lu mixture could also provide additional benefits such as a lower calorific content than conventional GOS or other beneficial properties attributed to lactulose ([@B11]; [@B38]).

To address this study, we have investigated the molecular response of *B. pseudocatenulatum* CECT 7765 when cultured in the presence of either glucose or GOS-Lu as carbon source. To do so, we have used three different high-throughput approaches: (i) genomic DNA sequencing for whole-genome assembly and functional annotation of the strain studied; (ii) a preliminary and exploratory single-replicated transcriptome approach of RNA pools to detect potential signals of over-expression across the *B. pseudocatenulatum* CETC 7765 genome during GOS-Lu fermentation, followed by validation of certain gene expression patterns by qPCR; and (iii) metabolite analysis of GOS-Lu species using gas chromatography coupled to mass spectrometry (GC--MS) to understand the upregulated metabolic pathways, the final output and potential biological consequences.

Materials and Methods {#s1}
=====================

Enzymatic Synthesis of GOS-Lu
-----------------------------

GOS-Lu were enzymatically synthesized via hydrolysis and transgalactosylation of lactulose (Duphalac^®^, Solvay Pharmaceuticals, Weesp, Holland) using a β-galactosidase from *Aspergillus oryzae* and following previously described methods ([@B13]). Then, the GOS-Lu mixture was treated with activated charcoal to remove the monosaccharide fraction ([@B24]). The final GOS-Lu composition was: 72% carbohydrates, 15% water, and 10% mineral salts. According to previous ESI-MS analysis, GOS-Lu predominantly consisted of di- and tri-saccharides (42 and 31% of total carbohydrates, respectively), followed by tetra- and penta-saccharides (25% of total carbohydrates), whereas only 2% were monosaccharides ([@B36]).

Bacterial Growth
----------------

*Bifidobacterium pseudocatenulatum* CECT 7765 was isolated from a breast-fed infant subject of a prospective observational study carried out in a cohort of 164 healthy full-term newborns, with a first degree relative affected by celiac disease. Ethics committee approvals for that study, according to the Helsinki Declaration of 1983, are already published ([@B48]). *B. pseudocatenulatum* CECT 7765 was grown overnight in low glucose modified MRS broth (10 g/L peptone, 8 g/L meat extract, 4 g/L yeast extract, 5 g/L sodium acetate, 2 g/L di-ammonium citrate, 0.2 g/L magnesium sulfate, 0.05 g/L manganesum sulfate, 2 g/L di-potassium phosphate, 0.1% v/v polysorbate 80) supplemented with 0.05% (w/v) [L]{.smallcaps}-cysteine and 0.5% (w/v) glucose at 37°C under anaerobic conditions into Whitley DG250 Anaerobic Workstation (don Whitley Scientific, Inc., Shipley, UK). A 5 mL aliquot of an overnight culture was obtained for genomic DNA isolation. For RNA isolation, over-day cultures were obtained by refreshing 1/100 overnight cultures in pre-warmed and oxygen-depleted modified MRS media supplemented with 0.05% (w/v) [L]{.smallcaps}-cysteine and containing 1% (w/v) glucose or 1% (w/v) GOS-Lu as sole carbon sources. Early exponential growth phase cultures were collected after 7--8 h of incubation, when optical density at 600 nm (OD 600) was approximately 0.4, to optimally detect differential gene expression patterns, as previously described ([@B21]), and to measure the residual fraction of GOS-Lu components. Stationary growth phase cultures were collected to measure accumulation of branched-chain amino acids in cell-free culture supernatants by LC with fluorescence detection. In both cases, cells were pelleted by centrifuging at 4°C and 2,500 × *g* for 20 min, and supernatants were aspired off and filtered using 0.22 μm disposable filters (Millipore).

Nucleic Acid Isolation
----------------------

DNA and RNA from respective bacterial cultures were isolated using MasterPure^TM^ Gram Positive DNA Purification Kit (Epicentre) with slight variations over manufacturer's instructions. Briefly, a cell lysis step was improved by incubating cell suspension with 500 μg Lysozyme (Sigma, Cat \#62970) and 20 U Mutanolysin (Sigma, Cat \#M9901) for 60 min at 37°C. For DNA isolation, samples were incubated with RNase A at 37°C for 60 min, whereas for RNA isolation samples were incubated with 2 U DNase I (Epicentre) at 37°C for 60 min instead of the RNase A treatment.

High-Throughput Sequencing
--------------------------

Ten μg genomic DNA from *B. pseudocatenulatum* CECT 7765 were sent to Eurofins Genomics GmbH (Ebersberg, Germany) to produce a shotgun library by fragmentation and end repair of DNA with an insert size of 300--400 bp and 2 bp × 150 bp (paired-end) configuration. The preliminary and exploratory transcriptome analysis was achieved by pooling RNA from three independent experiments in an equimolar mixture of glucose- or GOS-Lu-derived samples, respectively. Then, 30 μg total RNA per pool were also sent to Eurofins Genomics GmbH (Ebersberg, Germany) to produce cDNA libraries with an insert size of 150--400 bp and prior rRNA depletion using RiboZero^TM^ Magnetic Kit Gram-Positive Bacteria (Epicentre). DNA and cDNA libraries were pooled and sequenced in one MiSeq cell flow allowing 1/10 proportion of DNA library against cDNA libraries.

Data Analysis
-------------

The *B. pseudocatenulatum* CECT 7765 genome was assembled using the MIRA assembler ([@B12]). Scaffolding of contigs was assisted by SSPACE ([@B8]) and scaffold reordering was predicted by using comparative genomics and whole-genome alignment algorithms implemented in MAUVE ([@B14]) and draft genomes of close species such as *B. pseudocatenulatum* DSM 20438 (Accession number NZ_ABXX02000001). Predicted joints were corroborated by PCR and Sanger sequencing. Gene prediction and functional annotation were performed using tRNAscan-SE ([@B34]), RNAmmer ([@B31]), Prodigal ([@B28]), KEGG Automatic Annotation System ([@B40]), SMART database ([@B32]), Pfam database ([@B19]), CAZy database ([@B33]), CAT server ([@B49]), ScanProsite ([@B15]), and Artemis ([@B54]). Sequence information supporting the *B. pseudocatenulatum* CECT 7765 genome assembly was submitted to the European Nucleotide Archive (ENA) where it is publicly available under primary accession number PRJEB6926. Annotated 5S, 16S, and 23S rRNA gene sequences from *B. pseudocatenulatum* CECT 7765 are publicly available under ENA accession numbers LN624223, LN624224, and LN624525, respectively. Comparative genomics among *Bifidobacterium* species was accomplished using BRIG ([@B3]) and available and complete genome information from *B. breve* UCC2003 (NC_020517.1), *B. dentium* Bd1 (NC_013714.1), *B. longum* subsp. *infantis* ATCC 15697 (NC_017219.1), and *B. pseudocatenulatum* DSM 20438 (NZ_ABXX02000001, draft genome). The quality filtering and trimming of glucose- and GOS-Lu-derived RNA-seq analysis was performed using FASTX-toolkit ^[1](#fn01){ref-type="fn"}^. Read mapping was assisted using the local alignment Blast algorithm ([@B4]) and selecting alignments \>50% of read length (\>70 nt) and 100% identity. Read counts were normalized using RPKM ([@B41]) and the exploratory differential expression among glucose- and GOS-Lu-derived transcriptomes was measured with GFOLD. This analysis tool is able to detect potential trends in gene expression in unreplicated data, requiring further evaluation by conclusive methods like qPCR ([@B18]). In order to increase the stringency for detecting plausible signals of differential expression, we only selected genes with GFOLD score ≤-1 or ≥1. Sequence information supporting the *B. pseudocatenulatum* CECT 7765 transcriptome analysis was submitted to the ENA where it is publicly available under primary accession number PRJEB6928.

Quantitative PCR
----------------

The genes BPSEU7765_0088, BPSEU7765_0773, BPSEU7765_0523, BPSEU7765_0525, and BPSEU7765_1462 were selected from the preliminary and exploratory RNA-seq analysis to assess specific changes in expression by qPCR. The gene-specific oligonucleotides used for this aim are presented in the Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. The cDNA was synthesized using 5 μg of total and non-pooled RNA remaining from that used for the RNAseq approach (three replicates per treatment), and the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. The qPCR reactions were set in 96-well plates using the SYBR Green I Master Mix (Roche Lifesciences), 0.5 μM of forward oligonucleotide, 0.25 μM of reverse oligonucleotide, and 1 μL of the cDNA reaction. All treatment samples were set in triplicate in the plate and amplified in a LightCycler 480 II with the following cycling profile: initial incubation at 95° for 5 min and 35 cycles of 10 s at 95°, 20 s at 65°, and 15 s at 72°. Finally, the melting curve was set from 65 to 97° with a ramp rate of 0.11°/s. The expression level for each gene was measure according to the ΔΔCt method, using the expression of the 16S rRNA gene as calibrator, and expression of glucose samples as reference. RQ values were finally obtained with calculation of 2^-ΔΔCt^ for all samples and replicates. Differential expression was assessed by the one-sided *t-*test with Welch's correction supporting pairwise comparisons between gene expression under glucose and GOS-Lu treatments.

Quantitative Analysis of GOS-Lu Consumption by GC--MS
-----------------------------------------------------

Cell-free supernatants of *B. pseudocatenulatum* CECT 7765 cultures supplemented with GOS-Lu to replace glucose were obtained and analyzed by GC--MS using a two-step derivatization procedure (oximation and trimethylsilylation) according to previous methods ([@B27]). Trimethylsilyloximes (TMSO) derivatives of carbohydrates were identified by comparison of mass spectra and retention indices with standard derivatized carbohydrates, as described in a previous study ([@B25]). Characteristic mass spectra and data previously reported in the literature were used to identify those carbohydrates unavailable as commercial standards. Carbohydrate quantitative data were obtained from GC--MS peak areas using the internal standard method. To do so, standard solutions from 0.003 to 1 mg of phenyl-β-[D]{.smallcaps}-glucoside, sucrose, and raffinose were prepared to calculate the corresponding response factors relative to internal standard and used to quantify mono-, di-, and tri-saccharides, respectively. Analytical standards of fructose, galactose, lactulose \[β-[D]{.smallcaps}-galactopyranosyl-(1→4)-[D]{.smallcaps}-fructose\], lactose \[β-[D]{.smallcaps}-galactopyranosyl-(1→4)-[D]{.smallcaps}-glucose\], 1,6-galactobiose \[β-[D]{.smallcaps}-galactopyranosyl-(1→6)-[D]{.smallcaps}-galactose\], 1,4-galactobiose \[β-[D]{.smallcaps}-galactopyranosyl-(1→4)-[D]{.smallcaps}-galactose\], and 1,3-galactobiose \[α-[D]{.smallcaps}-galactopyranosyl-(1→3)-[D]{.smallcaps}-galactose\] were obtained from Sigma (St. Louis, MO, USA).

Quantitative Analysis of Branched-Chain Amino Acids
---------------------------------------------------

For valine (V), isoleucine (I) and leucine (L) analyses, samples were 1,000-fold diluted with 2 N acetic acid (BDH Prolabo) and subjected to an automatic pre-column derivatization with *o*-phthaldialdehyde (OPA; Sigma-Aldrich). For the derivatization step, 20 μl of diluted sample was mixed with 15 μl of 4 N NaOH (BDH Prolabo), 40 μl of OPA and 20 μl of 5% acetic acid in Milli-Q water and, then, 20 μl of the resulting mixture was injected into the LC system. Amino acids were separated by LC Gemini C-18 column (5 μm particle size, 250 mm × 4.6 mm i.d., Phenomenex) at a flow rate of 1 mL/min and 25°C. Solvent A was 0.15 M anhydrous sodium acetate (Sigma-Aldrich)/HPLC grade methanol (BDH Prolabo; 70:30, v:v) adjusted to pH 6.8 with glacial acetic acid (BDH Prolabo); solvent B was HPLC grade methanol/Milli-Q water (70:30, v:v). Elution was performed with a linear gradient as follows: 0--13 min, 50% B; 13--15 min, 100% B; 15--22 min, 100% B; 22--23 min, 50% B; 23--34 min, 50% B. Detection was performed by fluorescence using 340 and 455 nm for excitation and emission, respectively. Calibration curves of V, I, and L were built using commercial pure standards (0.1--1 ppm in 2 N acetic acid for I and L; 0.05--1 ppm in 2 N acetic acid for V) purchased from Sigma-Aldrich. Production of BCAAs was individually compared (V, I, or L) between treatments (GOS-Lu vs. Glucose) and differences were statistically analyzed with a one-sided *t-*test with Welch's correction.

Results
=======

*B. pseudocatenulatum* CECT 7765 Genome
---------------------------------------

The draft genome of *B. pseudocatenulatum* CECT 7765 comprised ∼2.25 Mbp containing six major super-scaffolds (ENA accession numbers: CDPW01000001 to CDPW01000006) with a 56.4% GC content, assembled from 138 contigs with N50 ∼145,000 bp and a theoretical coverage of 93X (MIRA assembler). At final assembly stage, the total number of genes predicted to be encoded by the *B. pseudocatenulatum* CECT 7765 genome was 1,879. Of these, 1,821 corresponded to coding genes, 54 tRNA genes, three rRNA genes clustered in a single operon, and one tRNA pseudogene with a CAT anticodon. This genome structure is quite similar to others from *B. psudocatenulatum* species recently sequenced ([@B1]). Additionally, a [C]{.ul}lustered [R]{.ul}egularly [I]{.ul}nterspaced [S]{.ul}hort [P]{.ul}alindromic [R]{.ul}epeats (CRISPRs) region was predicted. This region is characterized by 57 repeats of the ATTTCAATCCACGCTCTCCATGAGGAGAGCGAC sequence and a CRISPR-associated gene (*Cas*) annotated as BPSEU7765_1382 gene immediately downstream of the repetitive region. This feature indicates that *B. pseudocatenulatum* CECT 7765 can defend against bacteriophage attack with its innate immune system ([@B7]). Ribosomal RNA sequence information is publicly available in the ENA under accession numbers LN624223 to LN624225 for 5S, 16S, and 23S molecules, respectively. When the complete genomes (except for *B. pseudocatenulatum* DSM 20438) of representative species of the *Bifidobacterium* genus were compared, we could distinguish certain genomic regions differentially present in *B. pseudocatenulatum* CECT 7765 that are absent in other species, and even in one strain of the same species, *B. pseudocatenulatum* DSM 20438 (**Figure [1](#F1){ref-type="fig"}**). Consequently, we could distinguish six different genomic regions entirely and uniquely present in *B. pseudocatenulatum* CECT 7765, called Specificity Islands (SP1 to SP6) hereinafter. Functional analyses were made to disclose the potential gain-of-function in *B. pseudocatenulatum* CECT 7765 genome. In general terms, we found that functions distinctively found in the *B. pseudocatenulatum* CECT 7765 SPs were related to bacterial defense, and to carbohydrate transport and metabolism (**Figure [1](#F1){ref-type="fig"}**), and were sometimes duplicated. For instance, SP1 and SP2 show duplication in the cluster conformed by genes encoding DNA methylase, HTH_Tnp transposase and RelB antitoxin protein. These duplication events can be explained by the potential presence of transposases, predicted to be encoded in the respective SPs.

![**Comparative analysis of *Bifidobacterium pseudocatenulatum* CECT 7765 and close species.** Circular representation of *B. pseudocatenulatum* CECT 7765 (black inner line), *B. pseudocatenulatum* DSM 20438 (purple), *B. dentium* Bd1 (red), *B. breve* UCC2003 (blue), and *B. longum* subsp *infantis* ATCC 15697 (green) genomes. They are compared using whole-genome and blast-based alignment. Genomic regions exclusively found on *B. pseudocatenulatum* CECT 7765 are highlighted with dashed rectangles with functional annotation of genes present alongside, respectively.](fmicb-07-00624-g001){#F1}

As stated above, we observed a predominant gain of defense genes such as DNA methylases, restriction enzyme systems, and abortive phage infection proteins in the *B. pseudocatenulatum* CECT 7765 genome. Furthermore, there was a great variety of enzymes associated with carbohydrate metabolism and transport. Among them, we could distinguish genes coding for different metabolic functions such as glucosyltransferases, polysaccharide synthases, peptidoglycan-associated polymer synthases, and mono- (glucose and rhamnose) and tri-saccharide (raffinose) hydrolases, as well as multiple sugar transporters. Globally, the genome structure suggests that *B. pseudocatenulatum* CECT 7765 is strongly protected against phage infection by restriction modification systems located at SP2 (**Figure [1](#F1){ref-type="fig"}**), identified with locus tags BPSEU7765_0786 to BPSEU7765_0788, which account for a type I system with M, S, and R subunits, respectively. They appear to be additional to three other restriction modification systems, identified with locus tags BPSEU7765_708 to BPSEU7765_710 (type I), BPSEU7765_1106 (mrr protein of type IV system), and BPSEU7765_1110 to BPSEU7765_1112 (type III). Besides these bacterial immune system genes, we have also identified a CRISPR locus and a gene encoding a protein associated with the ability to abort active phage infections, the Abi protein (locus tag BPSEU7765_1115), previously reported in *Lactococcus* species ([@B5]; [@B22]). Furthermore, *B. pseudocatenulatum* CECT 7765 seems to have a wide repertoire of genes involved in mono-, oligo-, and poly-saccharide metabolism, which could facilitate its survival in the large intestine where complex oligosaccharides are the main energy source. To better understand the potential of *B. pseudocatenulatum* CECT 7765 to metabolize a wide variety of oligo- and poly-saccharides, we have annotated all its genes encoding active enzymes of the carbohydrate metabolism, according to CAZy database ([@B33]). Subsequently, we submitted the 1,821 ORF sequences, translated into amino acids, to the CAT server ([@B49]). Thus, we have obtained 252 enzymes annotated with the CAZy system, encoded by the *B. pseudocatenulatum* CECT 7765 chromosome. A comparative analysis indicates that the CAZy enzymes present in *B. pseudocatenulatum* CECT 7765 outnumber those present in *B. dentium* Bd1 (128 CAZy enzymes), *B. breve* UCC2003 (83), *B. longum* ATCC 15697 (70), and *B. pseudocatenulatum* DSM 20438 (97), all of which are fully annotated in the CAZy database. We detected the specific group of enzymes exclusively present in *B. pseudocatenulatum* CECT 7765 by drawing Venn diagrams ([@B6]) and disclosing the intersection lists of enzymes (**Figure [2A](#F2){ref-type="fig"}**). Consequently, we found that 33 CAZy families were exclusively found in *B. pseudocatenulatum* CECT 7765, whose associated functions are shown in **Table [1](#T1){ref-type="table"}**.

![***Bifidobacterium pseudocatenulatum* CECT 7765 and carbohydrate metabolism. (A)** Venn diagram showing the strain-specific and shared CAZy families among five *Bifidobacterium* species. **(B)** Growth curve comparison between *B. pseudocatenulatum* CECT 7765 cultures using Glucose (blue line) or GOS-Lu (red line) as carbon source. Growth was monitored measuring OD~600~ at 60 min intervals. The OD~600~ values are presented as a mean of three independent replicates (±SEM). The dashed square indicates the growth window for the exploratory transcriptome and qPCR analyses.](fmicb-07-00624-g002){#F2}

###### 

CAZy-based functional annotation of *Bifidobacterium pseudocatenulatum* CECT 7765 enzyme.

  CAZy family          Gene tag                                                                                        Functional annotation                                                EC number
  -------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------
  CBM27                BPSEU7765_0090, BPSEU7765_0322, BPSEU7765_0461, BPSEU7765_0481                                  Mannan-binding function                                              3.2.1.78
  CBM5,GH18            BPSEU7765_1720                                                                                  Chitin-binding + chitinase                                           3.2.1.14
  CE1                  BPSEU7765_0445, BPSEU7765_0719, BPSEU7765_0668, BPSEU7765_237, BPSEU7765_0946, BPSEU7765_1790   Acetylxylan esterase, feruloyl esterase                              3.1.1.72, 3.1.1.73
  GH73                 BPSEU7765_0412, BPSEU7765_0512                                                                  Mannosyl-glycoproteinendo-β-*N*-acetylglucosaminidase                3.2.1.96
  GH99                 BPSEU7765_0611                                                                                  Glycoprotein endo-α-1,2-mannosidase                                  3.2.1.130
  GT26                 BPSEU7765_0430, BPSEU7765_1630                                                                  UDP-ManNAc: β-*N*-acetyl-mannosaminyltransferase                     2.4.1.-
  GH72                 BPSEU7765_0266, BPSEU7765_0695                                                                  β-1,3-glucanosyltransglycosylase                                     2.4.1.-
  CBM32                BPSEU7765_1665                                                                                  *N*-acetylglucosaminidase                                            3.2.1.-
  CBM2                 BPSEU7765_0002, BPSEU7765_0052, BPSEU7765_1213, BPSEU7765_1468, BPSEU7765_1666                  Chitin, xylan, or cellulose-binding function                         3.2.1.4
  CE10                 BPSEU7765_0058, BPSEU7765_1710, BPSEU7765_1712                                                  Arylesterase, carboxyl esterase                                      3.2.1.3
  CBM35                BPSEU7765_0482, BPSEU7765_1803                                                                  Xylan-degrading enzyme                                               3.2.1.-
  GH39                 BPSEU7765_0340, BPSEU7765_0711, BPSEU7765_1241                                                  A-[L]{.smallcaps}-iduronidase, β-xylosidase                          3.2.1.76, 3.2.1.37
  CBM48, GH13, CBM41   BPSEU7765_0825                                                                                  Glycogen-binding function, α-amylase, α-glucansbinding               2.4.1.18, 3.2.1.1
  GH53                 BPSEU7765_0174, BPSEU7765_0476, BPSEU7765_1512, BPSEU7765_1516                                  Endo-β-1,4-galactanase                                               3.2.1.89
  GH76                 BPSEU7765_0339                                                                                  α-1,6-mannanase                                                      3.2.1.101
  GH17                 BPSEU7765_0112, BPSEU7765_0403, BPSEU7765_1389, BPSEU7765_1461                                  Glucan endo-1,3-β-glucosidase, glucan 1,3-β-glucosidase              3.2.1.39, 3.2.1.58
  GT30                 BPSEU7765_0219, BPSEU7765_0420, BPSEU7765_0721                                                  α-3-deoxy-[D]{.smallcaps}-manno-octulosonic-acid (KDO) transferase   2.4.99.-
  CE11                 BPSEU7765_0715                                                                                  UDP-3-0-acyl *N*-acetylglucosamine deacetylase                       3.5.1.-
  CBM48                BPSEU7765_0051, BPSEU7765_0971, BPSEU7765_1747                                                  Glycogen-binding function                                            2.4.1.18
  GH4                  BPSEU7765_1427                                                                                  α-glucuronidase, α-galacturonase, α-glucosidase                      3.2.1.139, 3.2.1.67, 3.2.1.22
  GT81                 BPSEU7765_0619                                                                                  NDP-Glc: glucosyl-3-phosphoglycerate synthase                        2.4.1.-
  GT34                 BPSEU7765_0063                                                                                  UDP-Gal: galactomannanα-1,6-galactosyltransferase                    2.4.1.-
  GT49                 BPSEU7765_0521                                                                                  β-1,3-*N*-acetylglucosaminyltransferase                              2.4.1.-
  CBM13                BPSEU7765_0179, BPSEU7765_1749                                                                  Xylanase A and arabinofuranosidase function                          3.2.1.8
  GT5                  BPSEU7765_0500, BPSEU765_0962                                                                   ADP-Glc: starch glucosyltransferase                                  2.4.1.21
  GH16                 BPSEU7765_0806                                                                                  Xyloglucosyltransferase, keratan-sulfate endo-1,4-β-galactosidase    2.4.1.207, 3.2.1.103
  GH92                 BPSEU7765_0869, BPSEU7765_1035, BPSEU7765_1492                                                  Mannosyl-oligosaccharide α-1,2-mannosidase                           3.2.1.113
  GT47                 BPSEU7765_0074                                                                                  Xyloglucan β-galactosyltransferase, heparanβ-glucuronyltransferase   2.1.1.-, 2.4.1.225
  CBM20                BPSEU7765_0263                                                                                  Granular starch-binding function                                     2.4.1.-, 3.2.1.-
  GT66                 BPSEU7765_1197                                                                                  Dolichyl-diphosphooligosaccharide---protein glycotransferase         2.4.99.18
  GH84                 BPSEU7765_1279                                                                                  *N*-acetyl β-glucosaminidase                                         3.2.1.52
  GT80                 BPSEU7765_0408                                                                                  β-galactoside α-2,6-sialyltransferase                                2.4.99.1
  GH103                BPSEU7765_0791                                                                                  Peptidoglycan lytic transglycosylase                                 3.2.1.-

The above results indicate that *B. pseudocatenulatum* CECT 7765 should be able to grow in the presence of a wide variety of carbon sources. This assumption was reflected in the fact it thrived on media supplemented with GOS-Lu instead of glucose (**Figure [2B](#F2){ref-type="fig"}**). Indeed, the doubling time (time to double the OD~600~ absorbance) at the exponential growth phase was slightly lower in the presence of GOS-Lu than in the presence of glucose (73.3 ± 3.8 min vs. 76.1 ± 0.7, respectively, *p* = 0.48). The ease with which it utilizes this prebiotic substrate seems to be a particular feature of this strain, not exhibited by other *Bifidobacterium* strains when cultured with GOS as carbon source ([@B35]; [@B20]; [@B62]). The species *B. pseudocatenulatum* has traditionally been considered an adult-type bifidobacteria, unlike *B. breve* and *B. longum* subsp. *infantis*, which are considered infant-type bifidobacteria ([@B52]). Nevertheless, *B. pseudocatenulatum* CECT 7765 was originally isolated from the stools of healthy breast-fed infants ([@B10]). The ability of this strain to occupy this niche and out-compete other colonizers could be explained by its adaptation to utilize a wide variety of oligosaccharides. Although, breast-milk composition is much more complex and oligo-galactose as such has only been found in small amounts in human milk ([@B57]), human-milk oligosaccharides could promote growth *in vivo* similarly to that observed *in vitro* when glucose is replaced by GOS-Lu.

Exploratory Analysis of the GOS-Lu-Associated Transcriptome
-----------------------------------------------------------

An exploratory RNA-seq approach has been used to analyze trends in differential gene expression in *B. pseudocatenulatum* CECT 7765 genome in response to either glucose or GOS-Lu as carbon source during anaerobic fermentation. With this approach, we detected transcripts in more than 99.3% of the coding genes initially predicted to be encoded by the *B. pseudocatenulatum* CECT 7765 genome, leaving sequence reads for just 12 genes unmapped. Globally, we wanted to explore potential signals of differential expression on the basis of measuring the GOS-Lu/glucose ratio of transcripts, thereby pinpointing the likely genomic regions responsible for GOS-Lu uptake and metabolism (**Figure [3](#F3){ref-type="fig"}**). This exploratory analysis showed that 76 different genes had a trend of up-regulation (GFOLD score ≥ 1) when GOS-Lu was used as carbon source (**Table [2](#T2){ref-type="table"}**) whereas 25 genes exhibited a tendency toward down-regulated (GFOLD score ≤-1) under the same condition (**Table [3](#T3){ref-type="table"}**). Altogether, we found five different gene clusters probably associated with GOS-Lu fermentation (see gene tags at top of **Figure [3](#F3){ref-type="fig"}**), which may represent a molecular signature for bacteria able to metabolize this carbon source. Interestingly, among these genes, there were membrane and periplasmic permeases as well as ABC transporters, beta-galactosidases, oligosaccharide metabolic enzymes, and transcriptional regulators, potentially associated with GOS-Lu fermentation (see functional annotation in **Table [2](#T2){ref-type="table"}**). We found that *B. pseudocatenulatum* CECT 7765 genome encodes a total of seven different beta-galactosidases (BPSEU7765_0525, BPSEU7765_1410, BPSEU7765_1435, BPSEU7765_1462, BPSEU7765_1517, BPSEU7765_1518, and BPSEU7765_1737), and five of these showed and indication to be over-expressed in the presence of GOS-Lu. Conversely, the BPSEU7765_1410 gene showed a signal for down-regulation (-1.82) and BPSEU7765_1737 had a neutral score for potential up- or down-regulation. This would suggest this couple of encoded enzymes may not be specific for GOS-Lu utilization. In addition to these likely expression patterns for beta-galactosidase genes, at least 20 different transporters/permeases seemed to be involved in GOS-Lu uptake (**Table [2](#T2){ref-type="table"}**). Particularly, the BPSEU7765_0523 and BPSEU7765_0524 ABC-type multiple sugar permeases showed an important over-expression trend under GOS-Lu exposure as compared to glucose in the medium. The cluster of genes BPSEU7765_0522 to BPSEU7765_0527 showed the strongest indication of over-expression in the presence of the prebiotic tested (**Figure [3](#F3){ref-type="fig"}**; **Table [2](#T2){ref-type="table"}**) and, therefore, they may potentially be the main elements mediating GOS-Lu uptake and utilization. This cluster would be primarily regulated by the BPSEU7765_0522 gene encoding for a LacI-type transcriptional regulator, which would simultaneously control expression of sugar transporters/importers (BPSEU7765_0523, BPSEU7765_0524, and BPSEU7765_0527) and the glycosyl hydrolases (BPSEU7765_0525 and BPSEU7765_0526).

![**Exploratory RNA-seq analysis throughout the *B. pseudocatenulatum* CECT 7765 genome.** A single-replicated RNA-seq approach, using pooled samples, was used to detect genomic regions displaying up- and down-regulation trends in response to GOS-Lu. Gene expression bias based on normalized GOS-Lu/Glucose ratios obtained from GFOLD analysis (see methods) is presented across the *B. pseudocatenulatum* CECT 7765 genome. Inner dashed lines indicate threshold to consider a likely up- or down-regulation (GFOLD score ≤-1 or ≥1, *p* \< 0.01). Clustered genes showing clear over-expression or down-regulation are highlighted in black or gray ovals. Tags of genes present in those regions are annotated in the text boxes at the top. The specific genetic structure of the gene cluster exhibiting the strongest expression change associated with GOS-Lu fermentation is shown below, with the respective KEGG-based functional annotation for each gene.](fmicb-07-00624-g003){#F3}

###### 

List of *B. pseudocatenulatum* CECT 7765 up-regulated genes during GOS-Lu fermentation.

  Gene tag         Functional annotation^1^   GFOLD score^2^   Description
  ---------------- -------------------------- ---------------- -----------------------------------------------------------
  BPSEU7765_0064   K01362                     1.41             Trypsin-like peptidase
  BPSEU7765_0087   PF07690                    2.35             MFS, ABC membrane transporter
  BPSEU7765_0088   K00053                     1.41             ilvC, ketol-acid reductoisomerase
  BPSEU7765_0113   K07243                     2.54             FTR, efeU, high-affinity iron transporter
  BPSEU7765_0114   PF10634                    2.41             Iron periplasmic transporter
  BPSEU7765_0115   No hits                    1.85             Unknown function
  BPSEU7765_0116   K09808                     1.57             ABC lipoprotein-releasing system permease
  BPSEU7765_0117   No hits                    1.40             Unknown function
  BPSEU7765_0118   PF12704                    1.56             MacB, FtsX, periplasmic ABC transporters
  BPSEU7765_0119   K02003                     1.59             ABC transport system
  BPSEU7765_0120   SM000900                   1.28             FMN binding, membrane Na(+) pump
  BPSEU7765_0125   K06191                     2.13             nrdH, glutaredoxin-like protein
  BPSEU7765_0190   K06910                     1.33             Phosphatidylethanolamine-binding protein
  BPSEU7765_0191   K08659                     1.24             pepDA, pepDB, dipetidase
  BPSEU7765_0327   K02346                     1.96             dinB, DNA polymerase IV
  BPSEU7765_0395   No hits                    1.09             Unknown function
  BPSEU7765_0419   K01784                     1.00             galE, UDP-glucose 4-epimerase
  BPSEU7765_0522   K02529                     2.71             lacI, galR, LacI family transcriptional regulator
  BPSEU7765_0523   K02025                     4.24             ABC MS P, multiple sugar transport permease
  BPSEU7765_0524   K02026                     4.03             ABC MS P1, multiple sugar transport permease
  BPSEU7765_0525   K12308                     3.46             bgaB, lacA, beta-galactosidase
  BPSEU7765_0526   K01209                     4.19             abfA, alpha-*N*-arabinofuranosidase
  BPSEU7765_0527   K10188                     3.99             lacE, araN, lactose/[L]{.smallcaps}-arabinose transporter
  BPSEU7765_0593   K03502                     1.49             umuC, DNA polymerase V
  BPSEU7765_0773   K00873                     1.37             Pyk, pyruvate kinase
  BPSEU7765_0810   No hits                    1.20             Unknown function
  BPSEU7765_0811   PF12704                    1.56             MacB, FtsX, periplasmic ABC transporters
  BPSEU7765_0812   K02003                     1.52             ABC transport system
  BPSEU7765_0828   K09014                     1.24             sufB, Fe--S cluster assembly protein
  BPSEU7765_0829   K09015                     1.00             sufD, Fe--S cluster assembly protein
  BPSEU7765_0831   K11717                     1.14             sufS, cysteine desulfurase
  BPSEU7765_0850   K06191                     2.07             nrdH, glutaredoxin-like protein
  BPSEU7765_0851   K03647                     2.25             nrdI, protein involved in ribonucleotide reduction
  BPSEU7765_0852   K00525                     2.51             nrdA, nrd Eribonucleosid-diphosphate reductase
  BPSEU7765_0853   No hits                    2.63             Unknown function
  BPSEU7765_0854   K00526                     2.22             nrdB, nrdF, ribonucleosid-diphosphate reductase
  BPSEU7765_0931   K01442                     1.09             Choloylglycine hydrolase
  BPSEU7765_0932   PF09819                    1.18             ABC-type cobalt transporter
  BPSEU7765_0954   K03701                     1.28             uvrA, excinuclease ABC subunit A
  BPSEU7765_1031   PF07690                    1.01             ABC membrane small-molecule transporter
  BPSEU7765_1086   K03593                     1.41             mrp, Chromosome partition ATP-binding protein
  BPSEU7765_1204   K03724                     1.30             lhr, ATP-dependent helicase
  BPSEU7765_1220   K03553                     1.11             recA, recombination protein
  BPSEU7765_1231   No hits                    1.56             Unknown function
  BPSEU7765_1285   K02565                     1.95             nagC, *N*-acetylglucosamine repressor
  BPSEU7765_1286   K00847                     1.40             scrK, fructokinase
  BPSEU7765_1304   SM000257                   2.48             LysM, bacterial cell wall degradation
  BPSEU7765_1305   K01356                     1.90             lexA, repressor LexA
  BPSEU7765_1389   K11104                     1.50             melB, melibiose permease
  BPSEU7765_1435   K01190                     1.55             lacZ, beta-galactosidase
  BPSEU7765_1461   K11104                     2.61             melB, melibiose permease
  BPSEU7765_1462   K01190                     3.29             lacZ, beta-galactosidase
  BPSEU7765_1463   PF00356                    2.89             lacI, galR, LacI family transcriptional regulator
  BPSEU7765_1464   K02529                     1.82             lacI, galR, LacI family transcriptional regulator
  BPSEU7765_1466   K00384                     1.05             trxB, thioredoxin reductase
  BPSEU7765_1467   K03386                     1.52             ahpC, peroxiredoxin (hydroperoxide reductase)
  BPSEU7765_1517   K12308                     1.21             bgaB, lacA, beta-galactosidase
  BPSEU7765_1518   K12308                     1.48             bgaB, lacA, beta-galactosidase
  BPSEU7765_1519   K02026                     1.16             ABC MS P1, multiple sugar transport permease
  BPSEU7765_1520   K10118                     2.21             msmF, raffinose/stachyose/melibiose transporter
  BPSEU7765_1521   K10117                     2.41             msmE, raffinose/stachyose/melibiose transporter
  BPSEU7765_1524   K06148                     1.15             ABCC-BAC transporter
  BPSEU7765_1552   K07749                     2.51             frc, formyl-CoA transferase
  BPSEU7765_1553   K07088                     3.74             Membrane transport protein
  BPSEU7765_1554   K01577                     3.95             Oxc, oxalyl-CoA decarboxylase
  BPSEU7765_1555   No hits                    1.02             Unknown function
  BPSEU7765_1577   K09760                     1.76             rmuC, DNA recombination protein
  BPSEU7765_1579   K03695                     1.69             clpB, ATP-dependent Clp protease
  BPSEU7765_1612   No hit                     1.58             Unknown function
  BPSEU7765_1613   No hit                     1.34             Unknown function
  BPSEU7765_1649   K00965                     1.03             galT, UDPglucose-1-phosphate urydyltransferase
  BPSEU7765_1673   K17686                     1.51             copA, Cu+ exporting ATPase
  BPSEU7765_1722   K02529                     1.50             lacI, galR, LacI family transcriptional regulator
  BPSEU7765_1733   K02025                     1.66             ABC MS P, multiple sugar transport permease
  BPSEU7765_1766   K15770                     1.18             ganO, maltooligosaccharideoligomertransporter
  BPSEU7765_1768   K00705                     1.10             malQ, 4-alpha-glucanotransferase

1

Functional annotation primarily presented from KEGG, when KEGG Orthology (KO) assignment is lacking, SMART or Pfam domain architecture is presented (SM or PF codes, respectively).

2

The GFOLD analysis can detect potential trends of gene expression in unreplicated data but require further evaluation by other methods such as qPCR. A GFOLD score other than zero indicates probable differential expression between two genes under two different conditions, an inference based on Bayesian probabilities of log

2

fold-change per gene across the genome (

p

= 0.01;

Feng et al., 2012

). Threshold for selection of probable up-regulated genes was ≥1 whereas GFOLD values ≤1 were set for selecting genes likely down-regulated during GOS-Lu fermentation.

###### 

List of *B. pseudocatenulatum* CECT 7765 down-regulated genes during GOS-Lu fermentation.

  Gene tag         Functional annotation^1^   GFOLD score^2^   Description
  ---------------- -------------------------- ---------------- -----------------------------------------------------------
  BPSEU7765_0182   K01854                     -1.11            glf, UDP-galactopyranose mutase
  BPSEU7765_0187   K02529                     -1.97            lacI, galR, LacI family transcriptional regulator
  BPSEU7765_0188   PF00381                    -3.48            PTS carbohydrate transport system
  BPSEU7765_0189   K08483                     -3.92            PTS-EI, ptsI phosphotransferase system
  BPSEU7765_0386   K02757                     -4.60            PTS-Bgl beta-glucosidase-specific IIC component
  BPSEU7765_0387   K03488                     -2.81            bglG, beta-glucosidasetranscriptionalantiterminator
  BPSEU7765_0478   K02025                     -1.00            ABC MS P, multiple sugar transport permease
  BPSEU7765_0586   K01817                     -2.13            trpF, phophoribosylanthranilate isomerase
  BPSEU7765_0587   K13954                     -2.34            yiaY, alcohol dehydrogenase
  BPSEU7765_0588   K01239                     -2.77            iunH, purine nucleosidase
  BPSEU7765_0589   PF07690                    -2.59            ABC membrane small-molecule transporter
  BPSEU7765_1024   No hits                    -1.72            Unknown function
  BPSEU7765_1408   PF07690                    -1.35            ABC membrane small-molecule transporter
  BPSEU7765_1410   K12308                     -1.82            bgaB, lacA, beta-galactosidase
  BPSEU7765_1458   K02003                     -1.09            ABC transport system
  BPSEU7765_1459   K02004                     -1.05            ABC transport system permease
  BPSEU7765_1596   K00852                     -1.24            rbsK, ribokinase
  BPSEU7765_1626   K10188                     -3.89            lacE, araN, lactose/[L]{.smallcaps}-arabinose transporter
  BPSEU7765_1627   K02025                     -3.13            ABC MS P, multiple sugar transport permease
  BPSEU7765_1628   K02026                     -3.04            ABC MS P1, multiple sugar transport permease
  BPSEU7765_1629   K01238                     -1.39            Glycosyl hydrolase
  BPSEU7765_1724   K02564                     -1.08            nagB, glucosamine-6-phosphate deaminase
  BPSEU7765_1725   K12373                     -1.10            HEXA, hexosaminidase
  BPSEU7765_1776   PF13416                    -1.47            Bacterial extracellular solute-binding protein
  BPSEU7765_1777   K01187                     -1.13            malZ, alpha-glucosidae

1

Functional annotation primarily presented from KEGG, when KEGG Orthology (KO) assignment is lacking, SMART or Pfam domain architecture is presented (SM or PF codes, respectively).

2

The GFOLD analysis can detect potential trends of gene expression in unreplicated data but require further evaluation by other methods such as qPCR. A GFOLD score other than zero indicates probable differential expression between two genes under two different conditions, an inference based on Bayesian probabilities of log

2

fold-change per gene across the genome (

p

= 0.01;

Feng et al., 2012

). Threshold for selection of probable up-regulated genes was ≥1 whereas GFOLD values ≤1 were set for selecting genes likely down-regulated during GOS-Lu fermentation.

As a result of the above preliminary and exploratory RNA-seq analysis, five genes were selected to confirm over-expression. These were the BPSEU7765_0088 and BPSEU7765_0773 genes, which would participate in the BCAA metabolism according to KEGG annotation; and the BPSEU7765_0523, BPSEU7765_0525, and BPSEU7765_1462 genes, related to sugar metabolism (**Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}**). In all cases, their up-regulation was confirmed by qPCR experiments indicating a high expression level associated with GOS-Lu consumption (**Figure [4](#F4){ref-type="fig"}**). Linear regression analysis with GFOLD scores against RQ values for those genes tested indicated that there is a good correlation among results from both type of analyses (Pearson's *r* = 0.73).

![**Gene expression by qPCR.** The data derived from preliminary and exploratory RNA-seq approach for genes BPSEU7765_0088, BPSEU7765_0523, BPSEU7765_0525, BPSEU7765_0773, and BPSEU7765_1462 was used as starting point to evaluate their over-expression by relative quantification in a qPCR assay. RQ ± SEM values are presented for all genes analyzed using three independent replicates per treatment and the average expression under glucose exposure as reference (see RQ ∼ 1 for these samples). In all cases the differential expression was significantly higher in samples from cultures with GOS-Lu (RQ \> 5) than in those with glucose (*p* ≤ 0.05).](fmicb-07-00624-g004){#F4}

Metabolic Processes Likely Activated by GOS-Lu
----------------------------------------------

Based on the functional annotation of the genes potentially over-expressed with GOS-Lu as carbon source, according to the exploratory RNA-seq approach, we identified the metabolic pathways presumably activated during its fermentation using the KEGG module-based annotation. We observed fourteen different pathways/modules represented by the genes exhibiting a likely up-regulation. As expected, we detected probable activation of genes involved in galactose degradation (KEGG Module M00632) and saccharide, polyol, and in lipid transport (M00196, M00199, M00491, and M00207 modules). When GOS-Lu was used as carbon source we detected a tendency of over-expression in a wide variety of oxidoreductases, which would control and protect against oxidative stress by regulating NAD+, NADP+, or H~2~O~2~ levels in *B. pseudocatenulatum* CECT 7765. Likewise, we also detected over-expression signals for several genes responsible for DNA repair, which probably counteract potential DNA damage from ROS (oxygen-reactive species) produced by central metabolism and metabolic byproducts. Additionally, we observed that GOS-Lu would promote the expression of genes coding for the biosynthesis of purine and pyrimidines (M00049, M00050, and M00053 modules) and branched-chain amino acid (BCAAs = V, L, and I; M00019 and M00570 modules). Moreover, we detected a probable over-expression of pyruvate kinase (K00873), a key component of the machinery for carbohydrate degradation which is responsible for phosphoenolpyruvate (PEP) production, the common precursor of reduction pathways that produce short-chain fatty acids (SCFAs) ([@B16]). In order to confirm our preliminary findings, further supported by qPCR results showing a strong over-expression in the BPSEU7765_0088 and BPSEU7765_0773 genes associated to BCAA metabolism, we also measured the metabolic output of the BCAA metabolic pathways over-expressed during GOS-Lu fermentation. We measured BCAA released to the extracellular media during growth in the presence of either glucose or GOS-Lu, using LC and OPA-derivatization (**Table [4](#T4){ref-type="table"}**). We found an increase in all BCAA in the cell-free supernatants of *B. pseudocatenulatum* CECT 7765 cultures supplemented with GOS-Lu as carbon source, but only differences in leucine concentrations were significant (*p* ≤ 0.0371). Leucine concentrations were more than 11% higher in the supernatants of GOS-Lu cultures than in the supernatants of glucose cultures. *B. pseudocatenulatum* CECT 7765 was shown to ameliorate the metabolic and immune dysfunction of diet-induced obesity in mice, partly by reducing lipid absorption and exerting an anti-inflammatory effect ([@B10]; [@B42]). According to our present findings, the combination of this strain with GOS-Lu could theoretically mediate another beneficial effect against obesity via generation of leucine, given the role of this amino acid as nutrient sensor and inducer of satiety ([@B51]; [@B56]).

###### 

Quantification of extracellular BCAAs after GOS-Lu fermentation.

          Amino Acid   Reference glucose^ab^   Reference GOS-Lu^ab^   Glucose culture^c^   GOS-Lu culture^c^   Difference^d^ (%)   Significance (*p*-value)
  ------- ------------ ----------------------- ---------------------- -------------------- ------------------- ------------------- --------------------------
  BCAAs   Valine       315 ± 5                 280 ± 40               332 ± 18 (1.053)     302 ± 12 (1.077)    2.32                0.3702
          Isoleucine   230 ± 10                215 ± 25               213 ± 12 (0.928)     202 ± 8 (0.938)     1.13                0.4370
          Leucine      700 ± 1                 690 ± 10               697 ± 50 (0.929)     713 ± 29 (1.034)    11.33               0.0371

BCAAs, branched-chain amino acids; GOS-Lu, lactulose-derived galacto-oligosaccharides.

a

Data are mean (

n

= 3) ± SEM and expressed in

ppm

(part per million).

b

Reference samples consist in culture media before cell inoculum.

c

Values within parenthesis mean normalized values against reference values.

d

Difference is calculated as \[GOS-Lu/Glucose\]-1 and described in percentage.

Finally, some genes presented in the SP5 also exhibited an over-expression sign as a result of GOS-Lu fermentation. Thus, the corresponding predicted ORFs BPSEU7765_1612 and BPSEU7765_1613 would appear to be associated with GOS-Lu consumption by *B. pseudocatenulatum* CECT 7765. Although no functional information could be inferred for those genes according to databases, their genomic context suggests their involvement in sugar-nucleotide metabolism, given that they are flanked by ABC-MS multiple sugar transporters, a UPD glucose 6-dehydrogenase, a dTDP glucose 4,6-dehydratase, an alpha-[D]{.smallcaps}-xylose xylohydrolase, and a lactose/[L]{.smallcaps}-arabinose transporter.

GOS-Lu Species Preferentially Consumed by *B. pseudocatenulatum* CECT 7765
--------------------------------------------------------------------------

To further integrate metabolic data resulting from GOS-Lu fermentation by *B. pseudocatenulatum* CECT 7765, we measured the concentrations of derivated mono-, di-, and trisaccharides at baseline and after growth in the presence of GOS-Lu. We observed preferential utilization of saccharide species and, particularly, the disaccharide fraction. Specifically, consumption of disaccharides was estimated at 70% and the trisaccharide fraction decreased by about 37% on average (**Table [5](#T5){ref-type="table"}**). Additionally, we found that the extracellular concentration of monosaccharide components of lactulose increased by 30--40% (fructose and galactose, respectively; **Table [5](#T5){ref-type="table"}**). This observation can be explained by presence of glycosyl hydrolases anchored to the cell-wall surface. To test this, we searched for an amino acid motif in the 252 CAZy enzymes detected in *B. pseudocatenulatum* CECT 7765 (**Table [1](#T1){ref-type="table"}**) using the ScanProsite server ([@B15]) and the amino acid patterns recognized by sortase enzymes, responsible for covalent attachment of proteins to cell-wall surface in Gram-positive bacteria. We did not find any enzymes harboring the amino acid pattern associated with sortase B activity N-P-\[QK\]-T-N, but we did find five enzymes containing the extended amino acid pattern recognized by sortase A proteins \[LPSN\]-\[PAG\]-X-T-G ([@B59]; [@B60]). Among these, only one harbored a glycosyl hydrolase domain, encoded by the gene BPSEU7765_0825 (S-A-I-T-G motif at C-ter). Although, the above analysis could explain the increased concentration of monosaccharides in the extracellular medium, we cannot discount the potential release of intracellular glycosylhydrolases to the culture medium due to spontaneous cell lysis during culture and/or supernatant preparation. The main GOS-Lu species largely consumed by *B. pseudocatenulatum* CECT 7765 were lactulose, 1,4-galactosyl-\[1, 1-galactosyl\]-fructose and 6′ galactosyl-lactulose, which decreased by 71, 47, and 31%, respectively, after incubation. Additionally, other less predominant GOS-Lu species were also largely consumed, thus the disaccharides 1,4-galactobiose (E + Z isomers), 1,5-galactosyl-fructose, and 1,6-galactobiose were consumed at levels above 80%.

###### 

Quantification of GOS-Lu species before (Pre) and after (Post) incubation with *B. pseudocatenulatum* CECT 7765.

                                                                                    Concentration, mg/mL                   
  ----------------- -------------------------------------------------------- ------ ---------------------- --------------- -----
  Monosaccharides   Fructose                                                 6.6    0.07 (0.02)^a^         0.09 (0.00)     +29
                    Galactose                                                7.1    0.05 (0.02)            0.07 (0.02)     +40
                    Glucose                                                  7.2    0.009 (0.002)          0.003 (0.001)   -67
  Disaccharides     Lactulose                                                14.9   0.93 (0.08)            0.27 (0.15)     -71
                    1,4-galactobiose *E*^b^                                  15.2   0.010 (0.001)          0.001 (0.001)   -90
                    1,5-galactosyl-fructose 1                                15.3   0.016 (0.001)          0.001 (0.001)   -83
                    1,5-galactosyl-fructose 2+1,3-galactobiose *E*           15.4   0.05 (0.00)            0.02 (0.01)     -60
                    1,2 galactobiose *E* + unknown                           15.6   0.028 (0.002)          0.010 (0.003)   -64
                    1,4 galactobiose *Z*                                     16.0   0.012 (0.001)          0.003 (0.002)   -75
                    1,2 galactobiose *Z* + 1,3 galactobiose *Z*              16.3   0.008 (0.001)          0.003 (0.001)   -63
                    1,6 glucosyl-fructose 1                                  16.7   0.004 (0.001)          0.001 (0.001)   -75
                    1,6 glucosyl-fructose 2                                  16.8   0.003 (0.001)          0.001 (0.001)   -67
                    1,1,galactosyl-fructose                                  17.1   0.016 (0.001)          0.005 (0.003)   -69
                    1,6 galactobiose *E* + 1,1 galactosyl-fructose           17.4   0.04 (0.01)            0.02 (0.01)     -50
                    1,6 galactobiose Z                                       18.4   0.005 (0.001)          0.001 (0.001)   -80
  Trisaccharides    Unknown                                                  32.6   0.011 (0.002)          0.007 (0.001)   -36
                    Unknown                                                  33.2   0.015 (0.001)          0.011 (0.002)   -27
                    Unknown                                                  34.5   0.019 (0.005)          0.012 (0.001)   -37
                    Unknown                                                  34.7   0.10 (0.03)            0.04 (0.01)     -60
                    6′ galactosyl-lactulose 1                                35.0   0.20 (0.05)            0.15 (0.03)     -25
                    6′galactosyl-lactulose 2                                 35.4   0.33 (0.05)            0.21 (0.03)     -37
                    1,4-galactosyl- \[1, 1-galactosyl\]-fructose + unknown   35.8   0.17 (0.03)            0.09 (0.01)     -47
                    Unknown                                                  36.2   0.02 (0.01)            0.010 (0.001)   -50
                    Unknown                                                  36.5   0.003 (0.001)          0.002 (0.002)   -33
                    Unknown                                                  38.6   0.02 (0.01)            0.01 (0.02)     -50

a

Standard deviation in parenthesis (

n

= 3).

b

Reducing carbohydrates gives rise to two peaks corresponding to the TMS oximes of syn (E) and anti (Z) isomers after derivatization.

c

Reduction or increase in GOS-Lu mono-, di-, and tri-saccharide species was calculated as the relative percentage of the final concentration of those saccharides (GOS-Lu post) compared to their initial concentration (GOS-Lu pre), respectively.

Discussion
==========

We have assembled the draft genome of *B. pseudocatenulatum* CECT 7765 using DNA sequence analysis of high-throughput sequencing data. This bifidobacterial strain was isolated from a breast-fed infant, and shows preclinical efficacy preventing obesity and metabolic dysfunction. Through comparative genomics we have detected certain strain-specific genome regions in *B. pseudocatenulatum* CECT 7765 indicating a gain-of-function associated with carbohydrate uptake and metabolism. Further features found in the *B. pseudocatenulatum* CECT 7765 chromosome are indicative of its genome stability, for example regarding protection against phage infections. These traits are generally considered relevant for potential probiotic applications. In particular, we have disclosed four restriction modification systems, a CRISPR system, and a system to abort phage infections. To our knowledge, bifidobacteria usually present up to three restriction modification systems ([@B44], [@B45]), which means that *B. pseudocatenulatum* CECT 7765 would be the first bifidobacteria harboring a larger collection of such defense mechanisms. Regarding the number of enzymes related to saccharide metabolism, the CAZy annotation system ([@B33]) showed us that *B. pseudocatenulatum* CECT 7765 contains a larger set of these proteins when compared with complete genomes of close species. Sixty-seven of the 252 CAZy enzymes detected in the *B. pseudocatenulatum* CECT 7765 genome were found to be exclusive to this strain when compared with the genetic information of close species, and they were grouped into 33 different CAZy families.

An exploratory RNA-seq analysis using pooled samples enabled stool identify potential genes responsible for GOS-Lu fermentation, encoding a wide variety of sugar transporters and permeases. Also, the expression of five out of seven beta-galactosidases present in the *B. pseudocatenulatum* CECT 7765 genome was identified to be likely associated with GOS-Lu fermentation. The over-expression trend observed for some of those genes was further assessed through a qPCR approach. As a result, we confirmed the over-expression of the BPSEU7765_0088, BPSEU7765_0773, BPSEU7765_0523, BPSEU7765_0525, and BPSEU7765_1462 genes in response to GOS-Lu consumption. This fact, and the strong correlation between GFOLD scores and RQ values obtained for the respective genes, would confirm the reliability of the findings from the exploratory transcriptome analysis, as a result of the GOS-Lu consumption by *B. pseudocatenulatum* CECT 7765. Particularly, we found a specific gene cluster (BPSEU7765_0522 to BPSEU7765_0528 genes) that was strongly over-expressed when GOS-Lu was used as carbon source. Taking into account the pattern of GOS-Lu species consumption, we hypothesized this gene cluster could be directly involved in controlling the import and hydrolysis of di- and tri-saccharides shown to be preferentially taken-up by *B. pseudocatenulatum* CECT 7765. In addition, the functions of the probable over-expressed genes have been mapped to the main bacterial metabolic pathways using the KEGG hierarchical classification. We found that GOS-Lu fermentation would activate galactose, saccharide and polyol degradation, lipid transport, antioxidant response, DNA repair processes, and purine/pyrimidine and BCAA biosynthesis. We corroborated the specific response of these genes to GOS-Lu, demonstrating that GOS-Lu fermentation boosts leucine synthesis and release, by directly analyzing the metabolic products generated and performing qPCR of some of the transcripts tentatively over-expressed in the exploratory RNA-seq analysis. Therefore, the use of GOS-Lu could contribute to promoting *B. pseudocatenulatum* CECT 7765 growth in the gut and, additionally, the molecular and metabolic outputs obtained from these synbiotic interactions indicate its likely beneficial anti-obesity effects. These effects could be related to the role of leucine as nutrient sensor and inducer of satiety, via activation of the mTOR-S6K signaling pathway on the hypothalamus, which would promote expression of anorexigenic peptides ([@B56]). Nevertheless, the extent to which amino acids produced by intestinal bacteria can confer health benefits to the human host *in vivo* has yet to be demonstrated.
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